Citation Tools
S7a – New therapeutic candidates
S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study